Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Benralizumab 10 mg	562
Overall Study	STARTED	Benralizumab 30 mg	562
Overall Study	STARTED	Benralizumab 100 mg	562
Overall Study	STARTED	Placebo	568
Overall Study	COMPLETED	Benralizumab 10 mg	504
Overall Study	COMPLETED	Benralizumab 30 mg	489
Overall Study	COMPLETED	Benralizumab 100 mg	502
Overall Study	COMPLETED	Placebo	507
Overall Study	NOT COMPLETED	Benralizumab 10 mg	58
Overall Study	NOT COMPLETED	Benralizumab 30 mg	73
Overall Study	NOT COMPLETED	Benralizumab 100 mg	60
Overall Study	NOT COMPLETED	Placebo	61

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02155660/flow